Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1 - PubMed (original) (raw)
. 1999 Nov 5;274(45):32048-54.
doi: 10.1074/jbc.274.45.32048.
Affiliations
- PMID: 10542237
- DOI: 10.1074/jbc.274.45.32048
Free article
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1
P Delerive et al. J Biol Chem. 1999.
Free article
Abstract
Interleukin-6 (IL-6) is a pleiotropic cytokine, whose plasma levels are elevated in inflammatory diseases such as atherosclerosis. We have previously reported that peroxisome proliferator-activated receptor alpha (PPARalpha) ligands (fibrates) lower elevated plasma concentrations of IL-6 in patients with atherosclerosis and inhibit IL-1-stimulated IL-6 secretion by human aortic smooth muscle cells (SMC). Here, we show that aortic explants isolated from PPARalpha-null mice display an exacerbated response to inflammatory stimuli, such as lipopolysaccharide (LPS), as demonstrated by increased IL-6 secretion. Furthermore, fibrate treatment represses IL-6 mRNA levels in LPS-stimulated aortas of PPARalpha wild-type, but not of PPARalpha-null mice, demonstrating a role for PPARalpha in this fibrate action. In human aortic SMC, fibrates inhibit IL-1-induced IL-6 gene expression. Furthermore, activation of PPARalpha represses both c-Jun- and p65-induced transcription of the human IL-6 promoter. Transcriptional interference between PPARalpha and both c-Jun and p65 occurs reciprocally, since c-Jun and p65 also inhibit PPARalpha-mediated activation of a PPAR response element-driven promoter. This transcriptional interference occurs independent of the promoter context as demonstrated by cotransfection experiments using PPARalpha, p65, and c-Jun Gal4 chimeras. Overexpression of the transcriptional coactivator cAMP-responsive element-binding protein-binding protein (CBP) does not relieve PPARalpha-mediated transcriptional repression of p65 and c-Jun. Finally, glutathione S-transferase pull-down experiments demonstrate that PPARalpha physically interacts with c-Jun, p65, and CBP. Altogether these data indicate that fibrates inhibit the vascular inflammatory response via PPARalpha by interfering with the NF-kappaB and AP-1 transactivation capacity involving direct protein-protein interaction with p65 and c-Jun.
Similar articles
- DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha.
Delerive P, De Bosscher K, Vanden Berghe W, Fruchart JC, Haegeman G, Staels B. Delerive P, et al. Mol Endocrinol. 2002 May;16(5):1029-39. doi: 10.1210/mend.16.5.0826. Mol Endocrinol. 2002. PMID: 11981037 - Glucocorticoid repression of AP-1 is not mediated by competition for nuclear coactivators.
De Bosscher K, Vanden Berghe W, Haegeman G. De Bosscher K, et al. Mol Endocrinol. 2001 Feb;15(2):219-27. doi: 10.1210/mend.15.2.0591. Mol Endocrinol. 2001. PMID: 11158329 - Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway.
Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B. Delerive P, et al. Circ Res. 1999 Sep 3;85(5):394-402. doi: 10.1161/01.res.85.5.394. Circ Res. 1999. PMID: 10473669 - Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation.
Chinetti G, Fruchart JC, Staels B. Chinetti G, et al. Inflamm Res. 2000 Oct;49(10):497-505. doi: 10.1007/s000110050622. Inflamm Res. 2000. PMID: 11089900 Review.
Cited by
- Plasma membrane and brain dysfunction of the old: Do we age from our membranes?
Martín MG, Dotti CG. Martín MG, et al. Front Cell Dev Biol. 2022 Oct 6;10:1031007. doi: 10.3389/fcell.2022.1031007. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36274849 Free PMC article. Review. - Simultaneous changes in high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis and those underlying molecular mechanisms in novel SHRSP5/Dmcr rat.
Moriya T, Kitamori K, Naito H, Yanagiba Y, Ito Y, Yamagishi N, Tamada H, Jia X, Tsuchikura S, Ikeda K, Yamori Y, Nakajima T. Moriya T, et al. Environ Health Prev Med. 2012 Nov;17(6):444-56. doi: 10.1007/s12199-012-0273-y. Epub 2012 Mar 11. Environ Health Prev Med. 2012. PMID: 22407906 Free PMC article. - Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.
Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour JF, Roden M, Sacks F, Tacke F. Francque S, et al. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):24-39. doi: 10.1038/s41575-020-00366-5. Epub 2020 Oct 22. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33093663 Review. - Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease.
Wagner N, Wagner KD. Wagner N, et al. Int J Mol Sci. 2023 Jan 25;24(3):2345. doi: 10.3390/ijms24032345. Int J Mol Sci. 2023. PMID: 36768666 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous